Cold atmospheric plasma is a novel modality to combat chemoresistance in cancer cells

The current standard therapy of ovarian cancer is the combination of surgery and multiagent chemotherapy. Cancer drug resistance, in particular, acquired resistance, leading to therapeutic failure in the treatment of ovarian cancer treatment. Today, Cold atmospheric plasmas and plasma stimulated liquid are currently gaining increasing attention for oncotheraphy. Plasma contains chemical and physical agents and plasma treatment is transferring these agents to the target. Here, we report the effect of plasma as a novel technology alone and in combination with carboplatin for cisplatin resistance ovarian cells. To this end, the human ovarian cancer cell line (SKOV-3) cell line was cultured in physiological conditions and was seeded in a microplate. SKOV-3 cell lines were exposed to different plasma treatment conditions. Also, the combination treatment of plasma and carboplatin were conducted. Cell viability assay was performed to analyze cell death. Our result indicates plasma can destroy carboplatin resistance. Besides, plasma resensitized cisplatin resistance ovarian cells to chemotherapeutic agents. Our findings revealed plasma therapy could be important for future ovarian cancer treatment.